Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia
- DOI
- 10.1038/s41408-026-01551-6
- Published
- 2026-06-27
- Container
- Blood Cancer Journal
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41408-026-01551-6,
title = {Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia},
author = {Elias Jabbour and Caitlin R. Rausch and Hannah Goulart and Nitin Jain and Farhad Ravandi and Abhishek Maiti and Yesid Alvarado and Jan Burger and Musa Yilmaz and Issa Khouri and Partow Kebriaei and Jeffrey Jorgensen and Sa A. Wang and Xuemei Wang and Ejiroghene Mayor and Rebecca S. Garris and Nicholas J. Short and Hagop Kantarjian},
year = {2026},
journal = {Blood Cancer Journal},
doi = {10.1038/s41408-026-01551-6},
url = {https://doi.org/10.1038/s41408-026-01551-6}
}RIS
TY - JOUR TI - Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia AU - Elias Jabbour AU - Caitlin R. Rausch AU - Hannah Goulart AU - Nitin Jain AU - Farhad Ravandi AU - Abhishek Maiti AU - Yesid Alvarado AU - Jan Burger AU - Musa Yilmaz AU - Issa Khouri AU - Partow Kebriaei AU - Jeffrey Jorgensen AU - Sa A. Wang AU - Xuemei Wang AU - Ejiroghene Mayor AU - Rebecca S. Garris AU - Nicholas J. Short AU - Hagop Kantarjian PY - 2026 JO - Blood Cancer Journal DO - 10.1038/s41408-026-01551-6 UR - https://doi.org/10.1038/s41408-026-01551-6 ER -
APA
Jabbour, E., Rausch, C. R., Goulart, H., Jain, N., Ravandi, F., Maiti, A., Alvarado, Y., Burger, J., Yilmaz, M., Khouri, I., Kebriaei, P., Jorgensen, J., Wang, S. A., Wang, X., Mayor, E., Garris, R. S., Short, N. J., & Kantarjian, H. (2026). Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia. Blood Cancer Journal. https://doi.org/10.1038/s41408-026-01551-6
Source records
- crossref · retrieved 2026-09-26T23:03:12.168Z